🔗 Visit the ClinicalTrials.gov page for NCT01373047
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. | Clin Cancer Res | 2015 | 0.99 |
| 2 | Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. | Cancer Immunol Immunother | 2015 | 0.90 |
| 3 | Genetically engineered T cells for the treatment of cancer. | J Intern Med | 2013 | 0.83 |
| 4 | Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. | Cancer Gene Ther | 2014 | 0.83 |
| 5 | Immunotherapy for solid tumors--a review for surgeons. | J Surg Res | 2013 | 0.83 |
| 6 | Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. | Cancer Gene Ther | 2016 | 0.80 |
| 7 | Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. | Pediatr Blood Cancer | 2015 | 0.75 |